The most elegant way to solve a problem

is to prevent it...

Haermonics, pure at heart

Every day 250 patients die from postoperative heart surgery complications caused by residual blood and clots in the pericardial cavity. Complications that could have been easily prevented.

At Haermonics, we’ve developed an innovative flush-therapy that promises to make such complications a thing of the past.

Designed by a leading heart surgeon, rarely does something this simple, this effective… have such impact.

The Haermonics Laebroides®

“Why should surgeons accept working under 19th century conditions, putting our patients on a drainage system that is essentially the same as the system invented a century and a half ago…with all the risk and uncertainty that it brings?

I was really tired of all of this. It is not necessary.

So I developed a drainage system that brings us into the 21st century: The Haermonics Laebroides®. A simple, but highly effective device that continuously flushes and cleans the pericardial space, preventing complications from ever arising in the first place.

No more unevacuated blood and clots leading to a growing hematoma around the heart! With the Laebroides you get real time data, giving you insight and peace-of-mind, knowing that a simple flush is preventing complications and an unnecessary re-operation.

And it works. Really well. Our randomised trials with 160 flushed patients have seen 0 unnecessary reoperations.”

“There is no successful heart surgery
without successful post-operative care”

David R. Koolbergen, M.D. Ph.D.

Chief Medical Officer at Haermonics
Congenital Cardiothoracic Surgeon at Amsterdam UMC / Leiden UMC

A successful operation with strong vital signs!

How can we be so confident about a product that is not yet available? It’s because we have already done Randomized Clinical Trials with 340 patients (59% reduction in blood loss and ZERO reoperations), and have a patented design which has been tested out in an investigational device. Whereas many products’ true clinical validation comes only after the product is available, the Haermonics Laebroides® offers unusual security in that it has already been clinically validated. We are well on our way to launching – by 2023 – the only solution on the market that prevents post-operative heart surgery complications from happening in the first place.
working principle
investigational device
product impression

Join the journey?

Share your email address with us and we’ll share important milestones and developments with you.

The Haermonics team

Wouter Markus
CEO
Dave Koolbergen
Chief Medical Officer
Wanda Meijst
Clinical Trial Director
Eva Diephuis
Product Owner &
Clinical Researcher

Advisory board

Prof. Dr. Pieter Kappetein
Dr. Ir. Claus Schaffrath MD
Dr. Sjaak Deckers
Ir. Martin Walti MBA

Clinical advisory board

Prof. Dr. Pieter Kappetein (NL)
Dr. Bill Brinkman (US)
Dr. Vinayak Bapat (US)
Prof. Dr. Thierry Folliguet (F)
Prof. Dr. Thomas Modine (F)
Prof. Dr. Robert Klautz (NL)
Prof. Dr. Theodor Fischlein (D)

Vacancies

We have no vacancies at the moment.
If you feel you can be of value to the team, use the form below to get in touch with us.

Get in touch

Haermonics Head office
Microlab
Kastanjelaan 400
5616 LZ Eindhoven
The Netherlands

Haermonics Research office
Amsterdam UMC
Dept. of Cardiothoracic Surgery
Meibergdreef 9
1105 AZ Amsterdam
The Netherlands

Thank you for your interest!

Would you have 1 minute (literally) to answer 3 reseach queries we have?